Welcome to our dedicated page for Biomx SEC filings (Ticker: PHGE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BiomX Inc. (PHGE) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including Form 8-K current reports and other key documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on BiomX’s clinical-stage phage therapy programs, corporate actions and financing arrangements, and they complement the company’s press releases for investors researching PHGE stock.
BiomX’s recent Form 8-K filings describe several material events. These include the initiation and terms of a private placement of Series Y Convertible Preferred Stock and related warrants, with details on dividend rights, conversion mechanics, exercise prices, registration rights and stockholder approval requirements. Other 8-Ks outline the authorization and implementation of a one-for-nineteen reverse stock split of the common stock listed on NYSE American under the symbol PHGE, along with proportional adjustments to equity awards, warrants and convertible preferred stock.
Filings also document significant developments in BiomX’s clinical and operational landscape. The company has reported an FDA clinical hold on the U.S. portion of its BX004 Phase 2b study, subsequent FDA follow-up questions on a third-party nebulizer device, and the eventual discontinuation of the BX004 Phase 2b trial after internal review and Data Monitoring Committee recommendations. Additional 8-Ks describe cost-cutting measures, workforce reductions, and the decision by the board of BiomX Ltd., an Israeli subsidiary, to approve and authorize the filing of an application to commence insolvency proceedings. Lease termination terms for Adaptive Phage Therapeutics, LLC, a wholly owned subsidiary, are also set out in detail.
Through this page, users can review how BiomX reports on its BX011 and BX211 phage programs for diabetic foot disease, its capital structure changes, and board and governance matters. Stock Titan enhances these filings with AI-powered summaries that highlight key terms, clinical implications and capital market impacts, helping readers quickly understand complex items such as preferred stock designations, warrant adjustments, clinical trial disclosures and strategic alternatives discussed in BiomX’s SEC reports.
OrbiMed Israel GP Ltd., OrbiMed Israel BioFund GP L.P., Carl L. Gordon and Erez Chimovits filed Amendment No. 6 to their Schedule 13D on BiomX Inc. (ticker PHGE). The amendment is an exit filing that discloses the group has fallen below the 5% ownership threshold.
Key details:
- On 18 June 2025, OrbiMed Israel Partners ("OIP") sold 1,787,767 common shares of BiomX at $0.34 per share.
- After the sale, the group’s beneficial holdings consist solely of 276,150 shares (all issuable upon conversion of 223 Series X Non-Voting Convertible Preferred Stock and 2,538,500 warrants).
- This position represents 1.0% of BiomX’s 26.45 million shares outstanding (including the shares underlying the preferred stock and warrants).
- The filing emphasises that, as of 18 June 2025, the reporting persons are no longer beneficial owners of more than 5% of BiomX’s outstanding shares.
- The investment committee comprising Gordon and Chimovits continues to review the position and may buy or sell additional shares based on market conditions, but no specific future plans were disclosed.
Implications: The disposal of nearly 1.8 million shares by a long-standing institutional holder removes a significant block from the shareholder register and may affect market perception of insider confidence. However, the remaining warrants and preferred shares ensure the group still retains some exposure to BiomX’s future performance.